FY2024 Earnings Estimate for Masimo Issued By Zacks Research

Masimo Co. (NASDAQ:MASI - Free Report) - Investment analysts at Zacks Research upped their FY2024 earnings per share estimates for shares of Masimo in a research note issued on Tuesday, November 26th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical equipment provider will post earnings per share of $4.00 for the year, up from their previous estimate of $3.84. The consensus estimate for Masimo's current full-year earnings is $4.04 per share. Zacks Research also issued estimates for Masimo's Q4 2024 earnings at $1.39 EPS, Q1 2025 earnings at $0.89 EPS, Q2 2025 earnings at $0.99 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.20 EPS and FY2026 earnings at $4.84 EPS.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 EPS.

A number of other research firms have also recently commented on MASI. Raymond James upgraded Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 target price for the company in a research note on Wednesday, November 6th. BTIG Research raised their price objective on Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research report on Wednesday, November 6th. Piper Sandler increased their price target on shares of Masimo from $165.00 to $180.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Finally, Stifel Nicolaus reissued a "buy" rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $167.00.

Masimo Stock Down 0.8 %

MASI traded down $1.37 on Wednesday, hitting $170.89. The company had a trading volume of 534,498 shares, compared to its average volume of 677,370. Masimo has a 52-week low of $91.60 and a 52-week high of $178.27. The stock has a fifty day simple moving average of $145.90 and a 200-day simple moving average of $128.73. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The firm has a market capitalization of $9.15 billion, a P/E ratio of 118.80 and a beta of 0.97.

Institutional Investors Weigh In On Masimo

A number of institutional investors have recently made changes to their positions in the company. Edgestream Partners L.P. bought a new position in Masimo in the 2nd quarter valued at approximately $645,000. Simplify Asset Management Inc. raised its stake in shares of Masimo by 120.4% in the second quarter. Simplify Asset Management Inc. now owns 21,670 shares of the medical equipment provider's stock worth $2,729,000 after purchasing an additional 11,838 shares during the last quarter. ING Groep NV lifted its holdings in shares of Masimo by 143.3% during the third quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider's stock valued at $32,119,000 after purchasing an additional 141,900 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock valued at $185,869,000 after buying an additional 262,370 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider's stock worth $153,314,000 after buying an additional 360,497 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.